Grants4Apps Accelerator 2016: You imagine, Bayer supports

BayerThe Grants4Apps (G4A) Accelerator developed by Bayer invites health IT and technology startups to apply for the program's 2016 edition. This year, Bayer looks primarily into projects aimed at fostering patient-doctor feedback in the Women's Health field as well as those improving patient engagement in Cardiology, Oncology, Radiology and Ophthalmology, but Bayer is also interested in highly innovative software, hardware, technologies applied to digital health fields.

The selected 5 start-ups will get free office space for 100 days at Bayer's Pharmaceuticals headquarters in Berlin, where representatives of Bayer senior management will offer them top-level coaching. In addition, Bayer will provide a financial support of 50,000 Euro to each of the startups.

For the third year in a row, the Grants4Apps Accelerator welcomes startups from around the world, whose software services, technologies, and apps have the potential of creating value for physicians and patients. Projects can be submitted by May 31st, 2016.

"Since 2014, IT and technology passionates from all over the world, with a focus on health projects, are invited to apply for what might become their biggest development opportunity. We are more than proud of the project's echo, especially at a local level, with Bucharest being the 2nd city in overall submissions in 2015. Furthermore, Romania ranked 6th in terms of number of submissions received from all over the world, which is outstanding. We are confident that the 2016 edition will suscitate at least as much interest and local bright ideas will improve people's lives," said Ruxandra Pirojoc, Head of Communications for Bayer Romania and Bulgaria.

"At Bayer, we strongly believe in the power of the local community - Scientists, Technologists, Engineers, and Mathematicians in Bucharest, working or willing to work on projects regarding digital health and digital farming. This is why we have established a group on meetup.com, aimed at fostering innitiave and cooperation between professionals, while also serving as a networking and discussions platform. It is a local innitiave matching Bayer’s vision of open innovation and global cooperation," added George Nancu, IT Specialist at Bayer Romania.

In June, an expert jury from Bayer will select the five winners who will be invited to spend 3.5 months in the Accelerator on the Bayer Pharmaceuticals headquarters in Berlin from August to December 2016. Aside from the financial support to help developing their business, the startups will be offered free co-working space, mentoring and expert advice on business development, market research, financial planning, and pitching for investors. The goal for the startups in the program is to further develop their product and business model so they can obtain financing from other sources after the program.

Application forms for startups are available at the Grants4Apps website http://www.grants4apps.com/berlin

Bayer fully embraces new approaches of open innovation, such as the "CoLaborator" or crowdsourcing initiatives like "Grants4Targets", "Grants4Indications", "Grants4Apps" and "PartnerYourAntibodies".

Bayer: Science for a Better Life
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015.

Most Popular Now

GSK reaches agreement with Novartis to acquire ful…

GlaxoSmithKline plc (LSE/NYSE: GSK) today announces that it has reached an agreement with Novartis for the buyout of Novartis' 36.5% stake in their Consumer Healthcare Jo...

Canadian neuroscientists say daily ibuprofen can p…

A Vancouver-based research team led by Canada's most cited neuroscientist, Dr. Patrick McGeer, has successfully carried out studies suggesting that, if started early enou...

First proof a synthesized antibiotic is capable of…

A "game changing" new antibiotic which is capable of killing superbugs has been successfully synthesised and used to treat an infection for the first time - and could lea...

Merck partners with Medisafe to help improve medic…

Merck, a leading science and technology company, today announced a new collaboration with US-based Medisafe to help its cardiometabolic patients better manage medication ...

Novartis teams up with Harvard to develop next gen…

Novartis announced today that it is teaming up with scientists from the Wyss Institute for Biologically Inspired Engineering at Harvard University and the Dana-Farber Can...

Phase III data in The Lancet show Novartis siponim…

Novartis today announced that the full results from the Phase III EXPAND study of oral, once-daily siponimod (BAF312) in secondary progressive multiple sclerosis (SPMS) w...

Taking a standard prostate cancer drug with food b…

By taking a high-cost drug with a low-fat meal - instead of on an empty stomach, as prescribed - prostate cancer patients could decrease their daily dose, prevent digesti...

North and south cooperation to combat tuberculosis

Tuberculosis can be cured and could be eradicated. For this to happen, however, patients have to receive the right treatment. Researchers at the Makerere University and t...

New immunotherapy for lung cancer shows promise of…

In a groundbreaking development, results from a recent clinical trial to treat lung cancer show that a novel immunotherapy combination is surprisingly effective at contro...

Lokelma approved in the EU for the treatment of ad…

AstraZeneca today announced that the European Commission has granted marketing authorisation for Lokelma (formerly ZS-9, sodium zirconium cyclosilicate) for the treatment...

New targeted therapy schedule could keep melanoma …

Skin melanoma, a particularly insidious cancer, accounts for the vast majority skin cancer deaths and is one of the most common cancers in people under 30. Treatment for ...

Personalized tumor vaccine shows promise in pilot …

A new type of cancer vaccine has yielded promising results in an initial clinical trial conducted at the Perelman School of Medicine at the University of Pennsylvania and...